Who Paid My Doc
Cornelius Mietus
Optometrist, Vision Therapy Santa Barbara, CA Doctor of Optometry
NPI 1336276757 CMS profile 1056205
1125 Coast Village Rd, Santa Barbara, CA 93108
General payments
$230
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Cornelius Mietus of Santa Barbara, CA is reported in the CMS Open Payments database as having received $230 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 36th percentile of Optometrist, Vision Therapy profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $230 | 1 |
Beside peers
- Cornelius Mietus
- Optometrist, Vision Therapy median
- Middle half of Optometrist, Vision Therapy
- National median
In program year 2025, general payments to Cornelius Mietus were reported at $230. Among 159 Optometrist, Vision Therapy profiles paid that year, the median was $172 and the middle half received between $65 and $349.
Show as a table
| Year | Cornelius Mietus | Optometrist, Vision Therapy median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $149 | $42–$361 | $163 |
| 2020 | $0 | $59 | $20–$146 | $114 |
| 2021 | $0 | $114 | $43–$217 | $132 |
| 2022 | $0 | $130 | $46–$350 | $149 |
| 2023 | $0 | $153 | $70–$363 | $160 |
| 2024 | $0 | $157 | $71–$362 | $164 |
| 2025 | $230 | $172 | $65–$349 | $169 |
Breakdown
Billing to Medicare
Part B · data year 2024 · 7 billing codesPaid by Medicare
$14,653
Medicare patients
97
Services billed
319
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 53% | |
| Arthritis | 38% | |
| Atrial fibrillation | 25% | |
| Ischemic heart disease | 18% | |
| Chronic kidney disease | 18% | |
| Depression | 14% | |
| Cancer | 13% | |
| Diabetes | 12% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Optometrist, Vision Therapy in California
Alan Winkelstein
Optometrist, Vision Therapy · Temecula, CA
Beth Ballinger
Optometrist, Vision Therapy · Newport Beach, CA
Gary Polan
Optometrist, Vision Therapy · Pacific Palisades, CA
Leanne Liddicoat
Optometrist, Vision Therapy · Roseville, CA
Elizabeth Yeh
Optometrist, Vision Therapy · Pacific Palisades, CA
Brenda Coen
Optometrist, Vision Therapy · Citrus Heights, CA
Related records
Optometrist, Vision Therapy in California
Practitioners in the same specialty and state, ranked by reported value.
All Optometrist, Vision Therapy
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.